Table 4. Univariate and multivariate survival analysis in patients with hepatocellular carcinoma undergoing TACE.
| Overall survival | Number | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | CI | p | HR | CI | p | ||
| §All patients (n = 881) | |||||||
| Age (<65/≥65 years) | 373/508 | 0.933 | 0.801–1.088 | 0.377 | |||
| Sex (male/female) | 673/208 | 0.936 | 0.855–1.025 | 0.153 | |||
| HBsAg (negative/positive) | 466/415 | 1.1271 | 0.969–1.311 | 0.120 | |||
| Anti-HCV (negative/positive) | 572/309 | 0.894 | 0.764–1.048 | 0.167 | |||
| Alcoholism (no/yes) | 719/162 | 1.240 | 1.018–1.509 | 0.032 | |||
| aDiabetes mellitus (no/yes) | 651/226 | 1.041 | 0.873–1.240 | 0.656 | |||
| Ascites (absent/present) | 715/166 | 1.796.522 | 1.488–2.169 | <0.001 | 1.536 | 1.227–1.924 | <0.001 |
| Creatinine (<1/≥1 mg/dL) | 442/439 | 0.897 | 0.772–1.043 | 0.159 | |||
| Alanine transaminase (≤40/>40 IU/L) | 337/544 | 1.151 | 0.985–1.346 | 0.077 | |||
| aAlkaline phosphatase (<100/≥100 IU/L) 1.06 | 370/492 | 1.678 | 1.435–1.963 | <0.001 | 1.362 | 1.155–1.607 | <0.001 |
| INR of PT (<1/≥1) | 236/645 | 1.145 | 0.967–1.354 | 0.116 | |||
| Platelet (≥150,000/<150,000/μL) | 408/473 | 0.794 | 0.683–0.924 | 0.003 | |||
| Alpha-fetoprotein (<20/≥20 ng/mL) | 349/532 | 1.927 | 1.642–2.261 | <0.001 | 2.006 | 1.694–2.372 | <0.001 |
| Tumor nodules (single/multiple) | 442/439 | 1.152 | 0.990–1.339 | 0.067 | |||
| Maximal tumor diameter (≤5/>5 cm) | 450/431 | 2.031 | 1.743–2.366 | <0.001 | 1.791 | 1.510–2.124 | <0.001 |
| Vascular invasion (no/yes) | 724/157 | 2.511 | 2.075–3.039 | <0.001 | 1.999 | 1.622–2.464 | <0.001 |
| Performance status (0/1-4) | 521/360 | 1.779 | 1.521–2.081 | <0.001 | 1.463 | 1.221–1.751 | <0.001 |
| Albumin-Bilirubin grade | |||||||
| Grade 1 | 297 | 1 | |||||
| Grade 2 | 540 | 1.678 | 1.421–1.981 | <0.001 | 1.531 | 1.285–2.823 | <0.001 |
| Grade 3 | 44 | 1.501 | 1.251–1.801 | <0.001 | 1.525 | 0.976–2.382 | 0.064 |
HR, hazards ratio; CI, confidence interval; HCV, hepatitis C virus, INR, international normalized ratio; PT, prothrombin time
a: Missing data of DM and alkaline phosphatase in 4 (0.5%) and 19 (2.2%) patients, respectively.